Growth will be restrained in the biosimilar growth hormones submarket by steady uptake for branded therapies, high brand loyalty, as well as the launch of long-acting growth hormones.

ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.

The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.

With higher-cost therapies in development, combined with increasing burdens on healthcare budgets from ageing populations and rising disease incidence, market access is becoming more challenging in countries worldwide.

The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade.